enGene Holdings Inc. (ENGN) – What Are Brokerages Thinking About This Stock?

Posted by Stanley Muller on Nov 11th, 2026

enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) has received a consensus recommendation of “Hold” from the fourteen research firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $11.05.

ENGN has been the topic of several research reports. Jefferies Financial Group raised enGene to a “strong-buy” rating in a report on Tuesday, October 13th. Weiss Ratings lowered enGene from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 30th. Citigroup lowered enGene from a “market perform” rating to a “hold” rating in a research note on Friday, October 16th. HC Wainwright restated a “buy” rating on shares of enGene in a report on Friday, October 16th. Finally, Citizens Jmp reaffirmed a “market perform” rating on shares of enGene in a research note on Wednesday, September 9th.

Read Our Latest Stock Analysis on ENGN

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Siren L.L.C. increased its position in enGene by 57.5% in the first quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock worth $35,774,000 after purchasing an additional 1,916,895 shares during the last quarter. SR One Capital Management LP bought a new position in enGene during the second quarter valued at $1,293,607. Eversept Partners LP lifted its position in enGene by 12.0% during the first quarter. Eversept Partners LP now owns 510,543 shares of the company’s stock valued at $3,477,000 after purchasing an additional 54,708 shares during the last quarter. Monashee Investment Management LLC grew its stake in shares of enGene by 8.5% in the 1st quarter. Monashee Investment Management LLC now owns 320,000 shares of the company’s stock worth $2,179,000 after buying an additional 25,000 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of enGene by 651.1% in the 1st quarter. Renaissance Technologies LLC now owns 156,100 shares of the company’s stock worth $1,063,000 after buying an additional 135,318 shares in the last quarter. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene News Summary

Here are the key news stories impacting enGene this week:

Neutral Sentiment: A short-interest report states that enGene had 0 shares sold short as of November 10, despite describing the figure as a “large increase.” That inconsistency makes the report an unclear signal and not an obvious catalyst for the stock. Short interest report

enGene Stock Down 5.6%

Shares of NASDAQ ENGN opened at $1.67 on Friday. The company has a current ratio of 10.21, a quick ratio of 10.21 and a debt-to-equity ratio of 0.11. The firm’s fifty day moving average is $1.77 and its two-hundred day moving average is $4.11. enGene has a 52-week low of $1.40 and a 52-week high of $12.25.

enGene (NASDAQ:ENGN – Get Free Report) last released its quarterly earnings data on Tuesday, September 8th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.04). On average, analysts forecast that enGene will post -1.82 earnings per share for the current fiscal year.

enGene Company Profile

(Get Free Report)

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.